1 citations
,
January 2019 in “Research Journal of Pharmacy and Technology” This review presents analytical methods for estimating Thuja occidentalis in homeopathic mother tincture but reports no new clinical results, emphasizing its broad application in homeopathy.
December 2023 in “Materials Today Sustainability” Scientists made glow-in-the-dark dots from human hair that can detect iron, prevent counterfeiting, and reveal fingerprints.
7 citations
,
January 2009 in “Journal of Pharmacy Research” This study found that fractions of Tridax procumbens extract demonstrated significant antioxidant activity, comparable to standard ascorbic acid, in laboratory tests.
44 citations
,
November 2022 in “Frontiers in Immunology” This review discusses the role of toll-like receptors in cancer treatment, providing an overview of pre-clinical studies and clinical trials on TLR-targeted therapies and noting the challenges and future prospects.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
15 citations
,
December 2019 in “European Journal of Dermatology” This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.
September 2019 in “Asian Journal of Pharmaceutical and Clinical Research” In this study, researchers found that the methanolic seed extract of Tectona grandis, known for its use in traditional medicine, demonstrated strong analgesic properties in Swiss albino mice, being effective at doses of 200–250 mg/kg and safe up to 1000 mg/kg.
June 2025 in “International Journal of Science and Research (IJSR)” This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.
9 citations
,
October 2019 in “Dermatologic Therapy” This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.
The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.
2 citations
,
May 2024 in “The Turkish Journal of Gastroenterology” Tacrolimus treatment for autoimmune hepatitis can cause hair loss.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.
3 citations
,
October 1994 in “Journal of Labelled Compounds and Radiopharmaceuticals” This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.
26 citations
,
April 2019 in “Advances in wound care” This study found that tannic acid accelerated wound healing in rats by modulating inflammatory cytokines, increasing growth factors, and activating the Erk 1/2 pathway.
January 1981 in “Elsevier eBooks”
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
March 2026 in “Journal of Pakistan Association of Dermatologists” In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
January 2024 in “Dermatologic therapy” In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.
January 2023 in “Indian Dermatology Online Journal” This case report identifies a 23-year-old man with congenital triangular alopecia, a non-scarring alopecia characterized by preserved follicles and vellus hair, for which unnecessary interventions should be avoided.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” This study found that isoallopregnanolone reduced stress-induced tic-like behaviors and sensorimotor gating deficits in a mouse model of Tourette syndrome, suggesting potential therapeutic properties comparable to existing treatments like haloperidol and finasteride.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.
October 2025 in “Biomedicines” This study suggests that Terminalia chebula fruit extract may promote hair growth in androgenetic alopecia by activating specific signaling pathways and inhibiting 5α-reductase, showing effectiveness comparable to finasteride.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.
June 2020 in “Journal of Investigative Dermatology” This study observed that insurance coverage for oral tofacitinib in alopecia areata patients was difficult to obtain, with 71% of patients ultimately not receiving approval despite the drug's efficacy as an off-label treatment.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.